number
protect
immun
function
declin
age
along
physiolog
anatom
chang
contribut
increas
suscept
older
adult
infecti
diseas
suboptim
protect
immun
respons
vaccin
influenza
vaccin
costeffect
strategi
prevent
complic
influenza
viral
infect
howev
immunogen
effect
current
licens
vaccin
unit
state
prevent
complic
aris
influenza
prevent
death
caus
winter
month
older
adult
henc
crucial
understand
molecular
mechan
lead
immun
dysfunct
function
age
appropri
strategi
develop
enhanc
diseas
resist
immunogen
prevent
vaccin
includ
influenza
vaccin
older
adult
popul
dramat
increas
older
adult
popul
occur
global
due
improv
sanit
prevent
vaccin
develop
effect
antimicrobi
drug
advanc
medic
scienc
growth
older
adult
popul
major
impact
healthcar
social
servic
public
health
year
older
adult
account
total
popul
requir
billion
primari
healthcar
cost
hartman
et
al
repres
almost
healthcar
spend
cost
provid
healthcar
older
adult
age
time
greater
cost
younger
adult
older
adult
popul
usa
project
almost
doubl
aoa
declin
immun
function
lead
increas
suscept
infecti
diseas
poor
adapt
immun
respons
vaccin
key
characterist
age
miller
miller
exampl
increas
colon
bacteria
yeast
skin
mucos
surfac
respiratori
urogenit
tract
increas
suscept
viral
infect
reactiv
latent
viral
bacteri
infect
well
document
gardner
et
al
worley
eli
et
al
htwe
et
al
kovaiou
et
al
simmon
et
al
van
duin
shaw
gener
infecti
diseas
sever
acut
respiratori
syndrom
sar
west
nile
viru
respiratori
syncyti
viru
rsv
influenza
pneumococc
infect
tend
sever
complic
often
result
unfavor
outcom
among
older
adult
compar
healthi
adult
addit
efficaci
prevent
vaccin
bacteri
viral
target
declin
dramat
progress
age
among
older
adult
clearli
indic
dysregul
immun
statu
refer
immunosensc
consequ
alter
physiolog
anatom
function
ginaldi
et
al
aw
et
al
henc
review
address
statu
innat
adapt
immun
function
age
current
state
influenza
vaccin
efficaci
older
adult
strategi
need
consid
protect
influenza
innat
immun
consid
nonspecif
receiv
secondari
import
compar
antigenspecif
adapt
immun
function
late
howev
discoveri
tolllik
receptor
tlr
innat
immun
recogn
crucial
surviv
speci
therefor
understand
innat
immun
offer
newer
insight
develop
novel
immunomodul
antimicrobi
hoffmann
et
al
medzhitov
janeway
b
imler
hoffmann
sinc
discoveri
tlr
sever
pathogensens
receptor
famili
identifi
last
decad
bingl
craven
kang
et
al
lu
et
al
holmskov
et
al
yoneyama
et
al
martinon
tschopp
ting
davi
brown
takaoka
et
al
famili
evolv
overcom
microbi
strategi
metabol
need
order
elimin
tlr
express
either
solubl
molecul
cell
membran
vesicular
compart
cytosol
shown
fig
pathogen
sensor
recogn
structur
compon
pathogen
activ
signal
transduct
cascad
lead
gene
transcript
sever
outcom
activ
antibacteri
antivir
defens
secret
proinflammatori
cytokin
chemokin
tissu
repair
event
damag
activ
adapt
immun
respons
case
precis
structur
sequenc
pathogen
signatur
stimul
innat
immun
receptor
well
defin
dynam
barrier
infecti
diseas
epitheli
line
skin
gastrointestin
respiratori
urogenit
system
prevent
colon
entri
potenti
pathogen
bodi
interior
steril
ganz
epitheli
cell
express
sever
pattern
recognit
receptor
upon
recognit
molecular
signatur
pathogen
secret
antimicrobi
substanc
aid
destruct
pathogen
microb
ganz
et
al
schittek
et
al
zanetti
addit
epitheli
cell
turnov
reduc
microbi
load
mucos
secret
respiratori
urogenit
gastrointestin
tract
antibacteri
substanc
also
facilit
elimin
colon
similarli
antibacteri
compon
sweat
skin
secret
reduc
colon
microbi
load
schittek
et
al
zanetti
limit
inform
avail
statu
function
skin
lung
mucos
epitheli
layer
among
older
adult
epitheli
cell
turnov
rate
skin
slow
among
older
adult
reduc
secret
sweat
sebum
result
dryness
increas
microbi
colon
especi
pseudomona
proteu
speci
fig
pathogen
sensor
innat
immun
system
sever
famili
pathogensens
receptor
recogn
conserv
molecular
signatur
pathogen
local
variou
compart
within
cell
well
bodi
fluid
engag
receptor
lead
activ
innat
immun
system
elimin
pathogen
laub
alter
physiolog
state
may
contribut
delay
skin
wound
heal
thoma
reed
et
al
sorensen
et
al
gosain
dipietro
laub
alter
physiolog
anatom
chang
lung
also
contribut
poor
innat
immun
therebi
increas
microbi
colon
incid
pneumonia
meyer
chang
includ
reduc
elast
function
lung
muscl
reduc
mucociliari
clearanc
rate
decreas
oropharyng
clearanc
bacteria
decreas
phagocyt
activ
alveolar
macrophag
decreas
mucos
secret
meyer
et
al
meyer
meyer
similarli
increas
local
candida
speci
oral
urogenit
mucos
surfac
age
among
older
adult
shay
ship
sobel
case
influenza
infect
data
avail
statu
innat
immun
respons
epitheli
barrier
age
henc
detail
studi
address
status
pathogensens
mechan
age
requir
enabl
us
come
strategi
reduc
microbi
load
epitheli
surfac
enhanc
diseas
resist
primari
role
innat
immun
prevent
entri
pathogen
tissu
howev
number
factor
dose
infect
pathogen
immun
nutrit
statu
individu
determin
innat
immun
abl
prevent
colon
infect
pathogen
overcom
epitheli
defens
gain
access
tissu
myeloid
lineag
hemopoiet
stem
cell
bone
marrow
name
tissueresid
macrophag
dendrit
cell
recogn
pathogen
innat
immun
receptor
either
directli
scaveng
receptor
pathogen
bound
solubl
innat
immun
receptor
initi
phagocytosi
inflammatori
respons
interact
lead
secret
proinflammatori
cytokin
tnfa
attract
neutrophil
natur
killer
cell
site
infect
thu
creat
optim
prime
environ
initi
adapt
immun
respons
dendrit
cell
dc
captur
antigen
pathogen
matur
differenti
migrat
region
drain
lymph
node
stimul
antigenspecif
b
cell
lymphoid
lineag
origin
hemopoiet
stem
cell
follow
antigenspecif
clonal
expans
b
cell
invad
pathogen
pathogeninfect
cell
remov
specif
antibodi
cell
tissueresid
macrophag
play
major
role
pathogen
sens
elimin
tissu
repair
demonstr
previous
express
function
tlr
periton
well
splenic
macrophag
declin
age
use
murin
model
peripher
blood
mononuclear
cell
pbmc
human
renshaw
et
al
van
duin
et
al
van
duin
shaw
find
consist
previou
observ
macrophag
function
declin
age
although
molecular
mechan
clear
plowden
et
al
b
sebastian
et
al
macrophag
function
declin
age
abil
process
present
antigen
secret
proinflammatori
cytokin
chemokin
provid
costimulatori
signal
migrat
site
infect
document
age
anim
model
plowden
et
al
b
although
agerel
declin
acut
proinflammatori
respons
monocyt
identifi
studi
demonstr
increas
level
proinflammatori
cytokin
serum
cultur
supernat
vitro
stimul
monocyt
cultur
healthi
older
adult
compar
younger
adult
observ
led
franceschi
colleagu
coin
term
inflammag
indic
lowgrad
chronic
inflammatori
state
hallmark
age
franceschi
et
al
franceschi
increas
risk
advers
chang
health
older
adult
would
predict
high
level
proinflammatori
cytokin
frail
older
adult
opposit
found
low
level
cytokin
associ
frailti
differ
observ
may
account
base
type
polyclon
vs
antigenor
ligandspecif
durat
acut
vs
chronic
stimulu
van
den
biggelaar
et
al
although
addit
studi
need
clarifi
observ
differ
secret
proinflammatori
cytokin
age
anim
model
healthi
older
adult
frail
older
adult
clear
alter
proand
antiinflammatori
cytokin
secret
balanc
age
alberti
et
al
alter
affect
innat
adapt
immun
function
fig
addit
migrat
antigenbear
dc
sever
affect
age
anim
indic
prime
environ
adapt
immun
respons
suboptim
linton
et
al
although
care
studi
yet
perform
langerhan
cell
skin
appear
declin
number
age
function
also
declin
age
meyerson
laub
contrast
bone
marrowderiv
dc
gener
cocktail
cytokin
age
anim
human
found
adapt
immun
effect
gener
younger
counterpart
recal
memori
cell
respons
would
suggest
vitro
gener
bypass
agerel
defect
seen
ex
vivo
dc
lung
et
al
tesar
et
al
howev
primari
tlymphocyt
respons
remain
impair
spite
normal
dc
function
suggest
increas
antigen
costimul
threshold
age
tlymphocyt
consist
earlier
publish
data
hayn
et
al
sambhara
et
al
van
duin
et
al
unpublish
find
laboratori
indic
substanti
delay
mobil
dc
macrophag
lung
region
drain
lymph
node
follow
infect
influenza
viru
age
compar
younger
anim
suggest
alter
microenviron
declin
express
pathogen
sensor
specif
tlr
secret
cytokin
chemokin
also
observ
may
influenc
migrat
activ
differenti
function
macrophag
dendrit
cell
inde
recent
publish
studi
demonstr
poor
induct
costimulatori
molecul
monocyt
older
adult
follow
tlr
stimul
consist
observ
murin
model
renshaw
et
al
van
duin
shaw
use
adjuv
stimul
innat
immun
system
provid
costimul
supplement
cocktail
cytokin
along
antigen
time
immun
significantli
improv
adapt
immun
respons
stimul
antigenpres
cell
apc
sambhara
et
al
sambhara
et
al
hayn
et
al
henc
logic
formul
vaccin
older
adult
adjuv
induc
optim
prime
environ
adapt
immun
respons
hematopoiet
stem
cell
hsc
bone
marrow
give
rise
myeloidand
lymphoidcommit
stem
cell
myeloid
lineag
give
rise
monocyt
macrophag
dendrit
cell
lymphoidcommit
stem
cell
give
rise
lymphocyt
b
lymphocyt
go
educ
select
thymu
case
cell
bone
marrow
case
b
cell
process
remov
potenti
autoreact
clone
cell
educ
peripheri
toler
selfantigen
although
indirect
evid
hsc
number
declin
age
detail
studi
yet
done
determin
hsc
number
function
migrat
alter
age
wang
et
al
lambert
et
al
de
haan
van
zant
chang
cellular
bone
marrow
age
clearli
document
may
alter
local
cytokin
milieu
thu
affect
prolifer
differenti
seed
secondari
lymphoid
organ
lineagespecif
stem
cell
liang
et
al
antigenspecif
adapt
immun
respons
influenza
viru
infect
vaccin
mediat
b
lymphocyt
lymphocyt
contribut
humor
cellular
immun
influenza
helper
cell
secret
cytokin
b
lymphocyt
differenti
class
switch
follow
recognit
antigen
surfac
immunoglobulin
receptor
b
lymphocyt
undergo
differenti
becom
plasma
cell
secret
antibodi
antibodi
major
surfac
glycoprotein
influenza
virus
hemagglutinin
ha
neutral
viru
bind
conform
determin
ha
prevent
infect
antibodi
direct
second
major
surfac
glycoprotein
neuraminidas
na
limit
viru
releas
infect
cell
therefor
reduc
viru
replic
function
antiha
antibodi
usual
determin
hemagglutinationinhibit
hai
test
case
virusneutr
test
hai
titer
correl
protect
rate
popul
influenza
viral
infect
wood
et
al
due
high
mutat
rate
rna
viru
select
pressur
preexist
antibodi
human
act
circul
virus
influenza
virus
accumul
mutat
ha
na
gene
lead
antigen
drift
requir
strain
influenza
contain
vaccin
must
updat
everi
year
antigen
match
circul
strain
gener
known
humor
immun
respons
induc
influenza
vaccin
declin
age
howev
humor
immun
respons
measur
hai
titer
communitydwel
healthi
older
adult
centenarian
similar
observ
younger
adult
indic
age
alon
affect
antibodi
respons
influenza
vaccin
contribut
factor
declin
antibodi
respons
includ
comorbid
condit
chronic
diseas
frailti
well
poor
nutrit
stress
limit
physic
activ
preexist
humor
immun
due
annual
vaccin
older
adult
appear
impact
antibodi
respons
subsequ
vaccin
explain
poor
vaccin
efficaci
one
possibl
qualiti
durat
rather
magnitud
antibodi
respons
may
affect
howev
result
recent
studi
indic
may
case
de
bruijn
et
al
gardner
et
al
iorio
et
al
henc
addit
marker
immun
respons
may
need
predict
vaccin
efficaci
older
adult
popul
earlier
studi
laboratori
shown
serum
antibodi
titer
correl
suscept
influenza
viru
infect
among
older
adult
suggest
antibodi
cellular
immun
contribut
clinic
protect
influenza
ill
although
antibodi
respons
strainspecif
within
subtyp
provid
crossprotect
virus
subtyp
via
antibodydepend
cellmedi
cytotox
carri
nk
cell
macrophag
unlik
b
lymphocyt
lymphocyt
recogn
peptid
fragment
deriv
antigen
present
major
histocompat
complex
molecul
profession
antigenpres
cell
dendrit
cell
lymphocyt
consist
helper
cell
cytotox
cell
lymphocyt
recogn
peptid
process
exogen
antigen
eg
kill
viru
present
class
ii
mhc
molecul
lymphocyt
recogn
peptid
fragment
deriv
endogen
antigen
eg
peptid
deriv
viru
replic
insid
cell
present
class
mhc
molecul
depend
pattern
cytokin
secret
lymphocyt
classifi
helper
helper
helper
helper
cell
lymphocyt
recogn
peptid
fragment
deriv
surfac
glycoprotein
intern
protein
surfac
glycoprotein
ha
na
vari
due
antigen
drift
shift
intern
protein
name
nucleoprotein
matrix
protein
other
fairli
conserv
within
subtyp
influenza
virus
shown
although
lymphocyt
prevent
infect
cytotox
lymphocyt
kill
virusinfect
cell
aid
viral
clearanc
thu
contribut
clinic
protect
influenza
ill
yap
et
al
henc
activ
lymphocyt
provid
crossprotect
variant
virus
within
subtyp
viru
infect
induc
robust
lymphocyt
respons
persist
long
time
provid
crossprotect
mice
magnitud
durabl
lymphocyt
respons
depend
rout
infect
immun
whether
vaccin
formul
induc
recal
especi
lymphocyt
respons
current
inactiv
splitviru
influenza
vaccin
provid
exogen
antigen
stimul
lymphocyt
thu
poor
induc
lymphocyt
respons
activ
recal
lymphocyt
respons
formul
vaccin
adjuv
stimul
antigenpres
cell
creat
optim
prime
environ
activ
lymphocyt
provid
broader
protect
serolog
distinct
virus
helper
cell
provid
growth
factor
b
lymphocyt
therebi
occupi
central
role
induct
humor
cellular
immun
respons
cell
defin
base
secret
ifng
cell
secret
ifng
follow
stimul
cell
stimul
secret
declin
cell
repertoir
due
thymic
involut
accumul
dysfunct
memori
cell
well
establish
mechan
observ
goe
beyond
explain
thymic
involut
alon
interleukin
appear
play
import
role
cell
surviv
thymic
recombin
event
expand
posit
select
thymocyt
hare
et
al
huang
et
al
agerel
reduct
product
within
thymu
may
respons
agerel
declin
thymic
output
cell
andrew
aspinal
ortman
et
al
human
accumul
anerg
cell
popul
age
especi
among
cell
subset
document
boucher
et
al
sansoni
et
al
molecular
mechan
lead
loss
known
boucher
et
al
sansoni
et
al
cell
anerg
stimul
antigen
mitogen
murin
studi
clearli
shown
clonal
expans
function
cell
significantli
reduc
compar
younger
counterpart
plowden
et
al
b
jiang
et
al
addit
helper
cytotox
cell
treg
cell
shown
play
import
role
regul
immun
respons
dejaco
et
al
hill
et
al
recent
publish
report
unpublish
find
show
signific
increas
treg
popul
function
age
may
contribut
poor
adapt
immun
respons
zhao
et
al
howev
direct
demonstr
role
treg
declin
immun
respons
age
lack
although
preliminari
result
indic
deplet
treg
subset
prior
immun
infect
viru
enhanc
humor
cellular
immun
respons
age
mice
compar
control
age
mice
increas
number
treg
age
may
aid
control
initi
autoimmun
disord
may
come
cost
reduc
effect
immun
respons
infecti
agent
evolutionari
signific
find
clear
function
cell
begin
elucid
mice
limit
inform
avail
role
human
impact
age
function
subset
bi
et
al
naka
et
al
chen
oshea
ctl
activ
shown
import
recoveri
influenza
viru
infect
absenc
seroprotect
antibodi
infect
viru
strain
mcelhaney
et
al
lymphocyt
recogn
peptid
fragment
deriv
viral
protein
bound
class
mhc
molecul
lyse
influenza
virusinfect
cell
lysi
target
cell
mediat
perforin
granulemedi
fasmedi
mechan
apasov
et
al
cell
cytolyt
activ
normal
measur
label
mhccompat
target
cell
either
puls
relev
peptid
infect
viru
cr
determin
amount
cr
releas
medium
h
addit
cell
martz
et
al
anoth
assay
assess
ctl
activ
measur
granzym
b
activ
lysat
influenza
virusstimul
pbmc
low
level
granzym
b
correl
risk
influenza
ill
older
adult
mcelhaney
et
al
mcelhaney
et
al
annual
influenza
epidem
caus
three
five
million
case
sever
ill
death
worldwid
world
health
organ
averag
year
unit
state
complic
influenza
infect
result
hospit
death
major
fatal
occur
among
elderli
popul
thompson
et
al
simonsen
et
al
complic
influenza
viral
infect
result
hospit
death
greatest
among
older
adult
peopl
chronic
medic
condit
immunolog
disord
infant
young
children
ie
year
age
whose
immun
system
still
matur
fior
et
al
vaccin
primari
strategi
reduc
morbid
mortal
associ
human
influenza
inactiv
detergentsplit
trival
influenza
vaccin
tiv
contain
two
influenza
virus
type
b
viru
well
liveattenu
nasal
influenza
vaccin
contain
three
compon
market
usa
inject
vaccin
recommend
peopl
risk
includ
person
age
year
older
live
influenza
vaccin
recommend
person
year
age
fda
older
adult
highrisk
group
influenzarel
death
goal
vaccin
popul
dhh
howev
recent
vaccin
rate
stagnant
coverag
still
hover
around
nation
center
health
statist
healthi
younger
adult
vaccin
may
effect
prevent
influenzalik
ill
vaccin
antigen
antigen
close
match
circul
epidem
strain
gross
howev
vaccin
efficaci
substanti
reduc
prevent
complic
influenza
infect
among
older
adult
nichol
et
al
mortal
benefit
influenza
vaccin
older
adult
hotli
debat
topic
simonsen
et
al
metaanalysi
cohort
older
adult
one
hmo
compris
data
ten
season
indic
vaccin
result
reduct
risk
hospit
due
influenza
reduct
risk
death
vu
et
al
howev
outcom
use
studi
includ
hospit
pneumonia
influenza
death
caus
influenzaspecif
despit
increas
vaccin
coverag
older
adult
sinc
decreas
influenzarel
excess
mortal
rate
among
older
adult
usa
thompson
et
al
simonsen
et
al
similarli
result
studi
netherland
italian
group
suggest
vaccin
result
reduct
excess
mortal
due
influenzalik
ill
although
enough
statist
power
gener
find
govaert
et
al
rizzo
et
al
ideal
random
placebocontrol
clinic
trial
clearli
defin
clinic
outcom
cultureposit
influenza
ill
rather
influenzalik
ill
pneumonia
allcaus
mortal
requir
evalu
benefit
vaccin
older
adult
howev
polici
decis
regard
vaccin
older
adult
make
placebocontrol
studi
ethic
unaccept
investig
mortal
benefit
influenza
vaccin
smith
shay
shown
previous
influenza
vaccin
effect
prevent
hospit
pneumonia
influenza
effect
prevent
death
caus
among
older
adult
low
intermedi
risk
respect
howev
among
older
adult
high
risk
due
comorbid
condit
vaccin
effect
prevent
hospit
death
respect
furthermor
efficaci
effect
vaccin
among
older
adult
stratifi
age
differ
pictur
emerg
efficaci
vaccin
prevent
ill
hospit
decreas
advanc
age
associ
comorbid
condit
suggest
old
older
adult
mount
optim
protect
immun
respons
vaccin
factor
impact
vaccin
efficaci
present
fig
immunosenesc
discuss
along
factor
influenc
outcom
number
strategi
induc
protect
immun
respons
influenza
present
fig
although
passiv
antibodi
influenza
consid
potenti
approach
prevent
therapeut
need
approach
merit
especi
older
adult
high
risk
frail
older
adult
exhibit
sever
immun
dysfunct
target
group
addit
infect
caus
drugresist
strain
influenza
pandem
strain
passiv
therapi
human
polyclon
antibodi
offer
potenti
therapeut
benefit
traggiai
et
al
lanzavecchia
et
al
simmon
et
al
current
transgen
anim
carri
human
immunoglobulin
gene
make
human
polyclon
immunoglobulin
immun
antigen
infecti
diseas
agent
avail
anim
serv
potenti
tool
gener
influenza
strainspecif
human
antibodi
passiv
transfer
fishwild
et
al
tomizuka
et
al
kuroiwa
et
al
buelow
van
schooten
clear
influenza
vaccin
need
formul
differ
older
adult
overcom
agerel
declin
immun
function
enhanc
immunogen
protect
level
humor
cellular
immun
respons
although
tiv
vaccin
market
europ
older
adult
shown
safe
immunogen
yet
approv
usa
podda
del
giudic
newer
adjuv
system
shown
enhanc
immunogen
viru
vaccin
may
provid
potenti
benefit
older
adult
popul
formul
season
vaccin
treanor
et
al
treanor
et
al
lerouxroel
et
al
sambhara
poland
increas
vaccin
dose
mg
ha
vaccin
compon
tiv
vaccin
potenti
option
enhanc
level
protect
antibodi
recent
multisit
phase
ii
random
doubleblind
clinic
studi
older
adult
receiv
mg
ha
compon
shown
gener
higher
level
hai
neutral
antibodi
compar
receiv
standard
vaccin
dose
mg
ha
compon
howev
vaccine
receiv
higher
dose
ha
experienc
local
system
reaction
receiv
standard
vaccin
dose
keitel
et
al
couch
et
al
result
consist
earlier
studi
concern
increas
vaccin
dose
produc
unaccept
local
reaction
effect
may
overcom
adjuv
vaccin
improv
respons
older
adult
anoth
possibl
vaccin
older
individu
influenza
season
order
boost
antibodi
respons
small
clinic
studi
revaccin
older
adult
twelv
week
later
enhanc
hi
titer
suggest
approach
may
viabl
altern
buxton
et
al
howev
one
caveat
studi
lack
baselin
titer
vaccine
receiv
second
dose
vaccin
henc
addit
studi
need
evalu
approach
viabl
strategi
enhanc
level
protect
antibodi
older
adult
popul
influenza
vaccineprevent
diseas
benefit
vaccin
prevent
infect
complic
aris
infect
among
adult
clearli
document
clear
immun
respons
declin
age
due
alter
innat
adapt
immun
function
vaccin
provid
adequ
protect
popul
henc
older
adultsa
major
target
popul
annual
influenza
vaccin
vaccin
efficaci
prevent
infect
low
risk
seriou
complic
infect
compound
increas
age
comorbid
condit
thu
effort
direct
formul
vaccin
adjuv
specif
older
adult
overcom
immunosenesc
passiv
immun
strategi
human
polyclon
antibodi
consid
addit
convent
serolog
assay
select
vaccin
candid
paramet
name
induct
cellular
immun
respons
well
activ
innat
immun
system
facilit
optim
microenviron
mobil
activ
differenti
matur
migrat
antigenpres
cell
consid
